Smithkline Beecham Corporation

Smithkline Beckman Corporation

Other

Glaxosmithkline LLC

Deborah Lynne Bryan

John Duncan Elliott

John G Gleason

Charles M Kinzig

Jerry Leroy Adams

Neil W Johnson

Domingos J Silva

James Francis Callahan

Timothy Francis Gallagher

Joelle Lorraine Burgess

Shinichiro Matsunaga

Jeffrey Michael Axten

Jiri Kasparec

Jun Tang

John D Elliott

David Harold Drewry

Hideyuki Sato

Thomas H Faitg

Yanhong Feng

Yasushi Miyazaki

Marcus Semones

Jeffrey M Ralph

Yutaka Maeda

Masato Nakano

Jean-Philippe Rocher

The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof;

Anthranilamide inhibitors of aurora kinase

Anthranilamide inhibitors of Aurora kinase

The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.

Compounds

Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof

This invention relates to novel quinoline inhibitors of hYAK1 and hYAK3 kinases and pharmaceutically acceptable salts, hydrates or solvates thereof, pharmaceutical compositions thereof, and methods of treatment of diseases in which an excessive amount of either such kinase is a factor.

Quinoline inhibitors of hyaki and hyak3 kinases

Novel indane and indene derivatives are described which are endothelin receptor antagonists.

Endothelin receptor antagonists

Cyclopentene derivatives as endothelin receptor antagonists

Esters of leukotriene A are conveniently prepared by reacting 9-oxo-5,6-trans-epoxynon-7(E)-enoates with 11-triphenylphosphoranylidene undec-6(Z),9(Z)-diene. Esters of leukotriene-A are useful intermediates in the synthesis of naturally occurring leukotrienes, which have been shown to be potent broncho-constricting substances. Novel intermediates to the esters of leukotriene A, 9-oxo-5,6-transepoxynon-7(E)-enoates and 7-oxo-5,6-trans-epoxyheptanoates, are disclosed.

Process for the preparation of esters of leukotriene A

Esters of leukotriene A are conveniently prepared by reacting 9-oxo-5,6-trans-epoxynon-7(E)-enoates with 11-triphenylphosphoranylidene undec-6(Z),9(Z)-diene. Esters of leukotriene-A are useful intermediates in the synthesis of naturally occurring leukotrienes, which have been shown to be potent broncho-constricting substances. Novel intermediates to the esters of leukotriene A. 9-oxo-5,6-trans-epoxynon-7(E)-enoates and 7-oxo-5,6-trans-epoxyheptanoates, are disclosed.

Esters of leukotriene A are conveniently prepared by reacting 9-oxo-5,6-trans-epoxynon-7(E)-enoates with 11-triphenylphosphoranylidene undec-6(Z),9(Z)-diene. Esters of leukotriene-A are useful intermediates in the synthesis of naturally occurring leukotrienes, which have been shown to be potent broncho-constricting substances. Novel intermediates to the esters of leukotriene A, 9-oxo-5,6-transepoxynon-7(E)-enoates and 7-oxo-5,6-transepoxyheptanoates, are disclosed.

Growing community of inventors

West Chester, PA, United States of America

Deborah Lynne Bryan